TCI Wealth Advisors Inc. Acquires 570 Shares of Pfizer Inc. (NYSE:PFE)

TCI Wealth Advisors Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,200 shares of the biopharmaceutical company’s stock after purchasing an additional 570 shares during the period. TCI Wealth Advisors Inc.’s holdings in Pfizer were worth $440,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. LGT Group Foundation raised its holdings in shares of Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock valued at $20,786,000 after purchasing an additional 18,274 shares during the last quarter. Creative Planning grew its stake in Pfizer by 17.1% in the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock worth $52,692,000 after acquiring an additional 266,167 shares in the last quarter. ORG Partners LLC lifted its stake in shares of Pfizer by 1,729.9% during the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock worth $1,327,000 after purchasing an additional 44,458 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in Pfizer by 10.3% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 256,460 shares of the biopharmaceutical company’s stock valued at $7,422,000 after purchasing an additional 23,928 shares in the last quarter. Finally, Everett Harris & Co. CA increased its stake in shares of Pfizer by 21.7% in the third quarter. Everett Harris & Co. CA now owns 218,344 shares of the biopharmaceutical company’s stock worth $6,319,000 after acquiring an additional 38,870 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on PFE shares. Sanford C. Bernstein began coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Citigroup started coverage on shares of Pfizer in a research report on Friday. They issued a “neutral” rating and a $30.00 price target for the company. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.37 during trading on Monday, reaching $28.82. The company had a trading volume of 11,851,698 shares, compared to its average volume of 36,729,313. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The stock has a market cap of $163.31 billion, a PE ratio of -481.67, a PEG ratio of 1.01 and a beta of 0.67. The business’s 50 day moving average price is $29.08 and its 200-day moving average price is $28.53.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the previous year, the firm posted $0.67 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.67 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.83%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.